Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab combinations in relapsed/refractory hematologic malignancies
NCT01592370Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Aug 2012
- Primary completion
- Sep 2020
- Modality
- Monoclonal Antibodies
- Countries
- 6
01
Overview
A Phase 2 trial of nivolumab in non-Hodgkin lymphoma (NHL), Hodgkin lymphoma (HL), multiple myeloma (MM), sponsored by Bristol Myers Squibb. Started Aug 2012; status: completed.
02
Drugs
03
Conditions
non-Hodgkin lymphoma (NHL)Hodgkin lymphoma (HL)multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01592370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01592370.